This is a preview of subscription content, log in via an institution to check access.
Notes
sponsored by Janssen Cilag
sponsored by Janssen de Mexico
Colombian pesos
Mexican pesos
References
Bertwistle D, et al. Cost-Effectiveness of Bendamustine Versus Fludarabine for First-Line Treatment of Chronic Lymphocytic Leukemia (Cll) in Colombia. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN119, 2 Nov 2013.
Bertwistle D, et al. The Cost-Effectiveness of Bendamustine Versus Fludarabine for the First-Line Treatment of Chronic Lymphocytic Leukemia (Cll) in Mexico. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN99, 2 Nov 2013.
Bertwistle D, et al. The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin's Lymphoma (Inhl) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Colombia. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN94, 2 Nov 2013.
Bertwistle D, et al. The Cost-Effectiveness of Bendamustine-Rituximab Versus Fludarabine-Rituximab for Patients with Indolent Non-Hodgkin's Lymphoma (Inhl) Who Have Progressed Following Treatment with Rituximab or a Rituximab-Containing Regimen in Mexico. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN110, 2 Nov 2013.
Rights and permissions
About this article
Cite this article
Bendamustine a worthy contender for CLL and NHL in Latin America. PharmacoEcon Outcomes News 692, 2 (2013). https://doi.org/10.1007/s40274-013-0882-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0882-8